Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-T cell therapy (First Affiliated Hospital of Harbin Medical University)
- Development stage
- Unknown
- Lead developer
- The First Affiliated Hospital of Harbin Medical University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CAR-T cell therapy (First Affiliated Hospital of Harbin Medical University) is an investigational cell-based immunotherapy designed for the treatment of pancreatic cancer. This program utilizes T cells genetically engineered to express chimeric antigen receptors (CARs) that target specific tumor-associated antigens frequently overexpressed in pancreatic malignancies, including Mesothelin (MSLN), Prostate Stem Cell Antigen (PSCA), Carcinoembryonic Antigen (CEA), Human Epidermal Growth Factor Receptor 2 (HER2), Mucin 1 (MUC1), and Epidermal Growth Factor Receptor variant III (EGFRvIII). The therapy aims to harness the patient's immune system to recognize and destroy malignant cells overexpressing these markers. It is currently being evaluated in a Phase 1 clinical trial (NCT02706405) to determine its safety profile and therapeutic efficacy in patients with advanced or metastatic pancreatic cancer.
- Other names
- Chimeric antigen receptor T cellCAR-T Immunotherapy for Pancreatic Cancer
02
Targets
EGFRvIII (Epidermal growth factor receptor variant III)ERBB2 (Erb-b2 receptor tyrosine kinase 2)MUC1 (Mucin-1 Antigen)MesothelinPSCA (Prostate stem cell antigen)
Beyond the preview
Go deeper on CAR-T cell therapy (First Affiliated Hospital of Harbin Medical University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-T cell therapy (First Affiliated Hospital of Harbin Medical University).